vs
Side-by-side financial comparison of CytoMed Therapeutics Ltd (GDTC) and Quantum Computing Inc. (QUBT). Click either name above to swap in a different company.
Quantum Computing Inc. is the larger business by last-quarter revenue ($198.0K vs $115.4K, roughly 1.7× CytoMed Therapeutics Ltd). CytoMed Therapeutics Ltd produced more free cash flow last quarter ($-855.4K vs $-12.2M).
CytoMed Therapeutics Ltd is a clinical-stage biopharmaceutical company focused on developing innovative allogeneic chimeric antigen receptor (CAR-T) cell therapies for treating hematological malignancies and solid tumors. It primarily serves global oncology patient populations and advances candidates targeting unmet medical needs in the immuno-oncology segment.
Rigetti Computing, Inc. is a Berkeley, California-based developer of superconducting quantum integrated circuits used for quantum computers. Rigetti also develops a cloud platform called Forest that enables programmers to write quantum algorithms.
GDTC vs QUBT — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $115.4K | $198.0K |
| Net Profit | — | $-1.6M |
| Gross Margin | — | -49.5% |
| Operating Margin | — | -11220.2% |
| Net Margin | — | -785.9% |
| Revenue YoY | — | 219.4% |
| Net Profit YoY | — | 97.0% |
| EPS (diluted) | — | $0.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $198.0K | ||
| Q3 25 | — | $384.0K | ||
| Q2 25 | $115.4K | $61.0K | ||
| Q4 24 | — | $62.0K | ||
| Q3 24 | — | $101.0K | ||
| Q2 24 | — | $183.0K | ||
| Q4 23 | — | $75.0K | ||
| Q3 23 | — | $50.0K |
| Q4 25 | — | $-1.6M | ||
| Q3 25 | — | $2.4M | ||
| Q2 25 | — | $-36.5M | ||
| Q4 24 | — | $-51.2M | ||
| Q3 24 | — | $-5.7M | ||
| Q2 24 | — | $-5.2M | ||
| Q4 23 | — | $-6.6M | ||
| Q3 23 | — | $-6.8M |
| Q4 25 | — | -49.5% | ||
| Q3 25 | — | 32.8% | ||
| Q2 25 | — | 42.6% | ||
| Q4 24 | — | 54.8% | ||
| Q3 24 | — | 8.9% | ||
| Q2 24 | — | 31.7% | ||
| Q4 23 | — | 13.3% | ||
| Q3 23 | — | 52.0% |
| Q4 25 | — | -11220.2% | ||
| Q3 25 | — | -2709.4% | ||
| Q2 25 | — | -16673.8% | ||
| Q4 24 | — | -14375.8% | ||
| Q3 24 | — | -5384.2% | ||
| Q2 24 | — | -2878.1% | ||
| Q4 23 | — | -8772.0% | ||
| Q3 23 | — | -13222.0% |
| Q4 25 | — | -785.9% | ||
| Q3 25 | — | 620.3% | ||
| Q2 25 | — | -59806.6% | ||
| Q4 24 | — | -82640.3% | ||
| Q3 24 | — | -5618.8% | ||
| Q2 24 | — | -2838.3% | ||
| Q4 23 | — | -8836.0% | ||
| Q3 23 | — | -13682.0% |
| Q4 25 | — | $0.03 | ||
| Q3 25 | — | $0.01 | ||
| Q2 25 | — | $-0.26 | ||
| Q4 24 | — | $-0.53 | ||
| Q3 24 | — | $-0.06 | ||
| Q2 24 | — | $-0.06 | ||
| Q4 23 | — | $-0.09 | ||
| Q3 23 | — | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $1.1B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $1.6B |
| Total Assets | — | $1.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.1B | ||
| Q3 25 | — | $555.6M | ||
| Q2 25 | — | $348.8M | ||
| Q4 24 | — | $78.9M | ||
| Q3 24 | — | $3.1M | ||
| Q2 24 | — | $2.5M | ||
| Q4 23 | — | $2.1M | ||
| Q3 23 | — | $7.4M |
| Q4 25 | — | $1.6B | ||
| Q3 25 | — | $877.9M | ||
| Q2 25 | — | $396.0M | ||
| Q4 24 | — | $107.3M | ||
| Q3 24 | — | $60.4M | ||
| Q2 24 | — | $65.5M | ||
| Q4 23 | — | $68.7M | ||
| Q3 23 | — | $72.2M |
| Q4 25 | — | $1.6B | ||
| Q3 25 | — | $898.2M | ||
| Q2 25 | — | $426.1M | ||
| Q4 24 | — | $153.6M | ||
| Q3 24 | — | $76.8M | ||
| Q2 24 | — | $76.0M | ||
| Q4 23 | — | $74.4M | ||
| Q3 23 | — | $89.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-855.3K | $-11.0M |
| Free Cash FlowOCF − Capex | $-855.4K | $-12.2M |
| FCF MarginFCF / Revenue | -741.5% | -6147.5% |
| Capex IntensityCapex / Revenue | 0.0% | 583.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-37.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-11.0M | ||
| Q3 25 | — | $-8.7M | ||
| Q2 25 | $-855.3K | $-6.1M | ||
| Q4 24 | — | $-3.8M | ||
| Q3 24 | — | $-4.6M | ||
| Q2 24 | — | $-4.0M | ||
| Q4 23 | — | $-5.0M | ||
| Q3 23 | — | $-4.4M |
| Q4 25 | — | $-12.2M | ||
| Q3 25 | — | $-11.5M | ||
| Q2 25 | $-855.4K | $-7.1M | ||
| Q4 24 | — | $-6.6M | ||
| Q3 24 | — | $-5.1M | ||
| Q2 24 | — | $-5.1M | ||
| Q4 23 | — | $-5.0M | ||
| Q3 23 | — | $-6.0M |
| Q4 25 | — | -6147.5% | ||
| Q3 25 | — | -3000.3% | ||
| Q2 25 | -741.5% | -11683.6% | ||
| Q4 24 | — | -10709.7% | ||
| Q3 24 | — | -5040.6% | ||
| Q2 24 | — | -2782.0% | ||
| Q4 23 | — | -6693.3% | ||
| Q3 23 | — | -12022.0% |
| Q4 25 | — | 583.8% | ||
| Q3 25 | — | 723.2% | ||
| Q2 25 | 0.0% | 1678.7% | ||
| Q4 24 | — | 4622.6% | ||
| Q3 24 | — | 508.9% | ||
| Q2 24 | — | 588.5% | ||
| Q4 23 | — | 70.7% | ||
| Q3 23 | — | 3168.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | -3.67× | ||
| Q2 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
